Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Last Updated: August 15, 2022

Details for Patent: 7,988,001

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,988,001 protect, and when does it expire?

Patent 7,988,001 protects SPIRIVA RESPIMAT and is included in one NDA.

Protection for SPIRIVA RESPIMAT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-nine patent family members in thirty-seven countries.

Summary for Patent: 7,988,001
Title:Container provided with a pressure equalization opening
Abstract: A process for producing a container comprising an outer container, an inner bag disposed therein and a pressure equalisation opening disposed in the outer container, and a container produced according to this process, is described, wherein a pre-moulding, comprising two coaxial tubes, is first produced by co-extrusion with the help of a blow mould and with an outwardly-projecting base seam being formed. The process forms a pressure equalisation opening in the outer container without endangering the integrity of the container, wherein a lower wastage rate and higher productivity are achieved. To do this, the base seam is partially cut off and a force which acts in the direction of the seam is introduced into the pre-moulding, which has a temperature of 40 degrees C. to 70 degrees C., which force breaks open and plastically deforms the base seam so that a pressure equalisation opening is formed in the base area.
Inventor(s): Kuehn; Torsten (Ingelheim, DE), Metzger; Burkhard Peter (Ingelheim, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE)
Application Number:11/778,715
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 7,988,001

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim SPIRIVA RESPIMAT tiotropium bromide SPRAY, METERED;INHALATION 021936-002 Sep 15, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Boehringer Ingelheim SPIRIVA RESPIMAT tiotropium bromide SPRAY, METERED;INHALATION 021936-001 Sep 24, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,988,001

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany100 17 443Apr 07, 2000
Germany100 17 443Apr 7, 2000

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.